Francini G. Montagnani M., Petrioli R.
Comparison between CEA, TPA, CA 15/3
and hydroxyproline, alkaline phosphotase in the follow — up of bone metastases in breast
cancer // Int. J. Biol. Markers. — 1990. — V. 5 (2). — P. 65 72.
Francini G., Gonnelli S., Petrioli R., Bruni S., Marsili S., Aquino A., Camporeale A.
Procollagen type I carboxy terminal propeptide as a marker of osteoblastic bone metas
tases // Cancer Epidemiol. Biomarkers Prev. — 1993. — V. 2(2). — P.125 129.
Francini G., Petrioli R., Maioli E., Gonnelli S., Marsili S., Aquino A., Bruni S.
Hypercalcemia in breast cancer // Clin. Exp. Metastasis. — 1993. — V. 11(5). —
P. 359 367.
Francis M.D., Slough C.L., Tofe A.J.
Disrtibution and effect of P32 EHDP in normal
and bone tumor bearing dogs // J. Nucl. Med. — 1976. — V. 17. — P. 548.
Francois M., James B., Morrison B.
Endogenous sex hormones, prolactin and breast
cancer in premenopausal women // J. Nation. Cancer Inst. — 1986. — V. 77. — ¹ 3. —
P. 613 616.
Frank J., Ling A., Patronas N., Carrasquillo J., Horvath K., Dwyer A.
Comparison of
magnetic resonance imaging and radionuclide bone scan in the evaluation of primary and
metastatic disease in the bone // Proc. A.S.C.O. — 1989. — V. 8 (abstr. 25).
Franklin R.B., Tashjian A.H.
Intravenous infusions of prostaglandin E2 raties plas
ma calcium in the rat // Endocrinology. — 1975. — V. 97. — P. 240 243.
Friedland J.
Local and systemic radiation for palliation of metastatic disease // Urol.
Clin. North. Am. — 1999. — V. 26(2). — P. 391 402.
Front D., Schnec S.C., Frankel A.
Bone metastases and bone pain in breast cancer.
Are they closely associated? // J.A.M.A. — 1979. — V.16. — P.1747 1748.
Frost H.M.
Bone remodelling and its relationship to metabolic bone disease //
Springfield: Thomas. — 1973.
Fukui A., Kawamura M., Kataoka M., Fujii T., Yamamoto K., Yoshioka S., Ikezoe J.
Clinical usefulness of 201Tl chloride scintigraphy for the evaluation of metastatic bone
lesions // Nippon Igaku Hoshasen Gakkai Zasshi. — 1998 V. 58(1). — P. 25 33.
Fulfaro F., Casuccio A., Ticozzi C., Ripamonti C.
The role of bisphosphonates in the
treatment of painful metastatic bone disease: a review of phase III trials // Pain. —
1998. — V. 78(3). — P. 157 169.
Funke I., Schraut W.
Meta analysis of studies on bone marrow micrometastases: an
independent prognostic impact remains to be substantiated // J. Clin. Oncol. — 1998. —
V. 16. — P. 557 566.
Furnival C.M., Blumgart L.H., Citrin D.L., McKillop J.H., Fogelman I., Greig W.R.
Serial scintiscanning in breast cancer: Indications and prognostic value // Clin. Oncol. —
1980. — V. 6. — P. 25 32.
Furr B.J.A., Jordan V.C.
The pharmacoligy and clinical uses of tamoxifen //
Pharmacol. and Ther. — 1984. — V. 25. —¹ 2. — P.127 205.
Gaines R.E., Cotes P.M.
International reference preparation of human prolactin for
immunoassay: deffinition of the international unit, report of a collaboratier study and com
parison of estimates of human prolactin made in various laboratories // J. Endocr. —
1979. — V. 80. — P. 157.
Gainor B.J., Buchert P.
Fracture healing in metastatic bone disease // Clin. Orthop. —
1983. — V. 178. — P. 297 302.
Galasko C.S.B.
Pathological fractures secondary to metastatic cancer // J. R. Coll.
Surg. Edinb. — 1974. — V. 19. — P. 351 362.
226
Êîñòíûå ìåòàñòàçû ðàêà ìîëî÷íîé æåëåçû
